Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):936–941. doi: 10.1038/bjc.1996.460

Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases.

A Platz 1, P Sevigny 1, T Norberg 1, P Ring 1, B Lagerlöf 1, U Ringborg 1
PMCID: PMC2074743  PMID: 8826861

Abstract

A common characteristic of cancer cells is unrestrained cell division. This may be caused by mutational changes in genes coding for components of cell cycle-controlling networks. Alterations in genes involved in G1 checkpoint control have been registered in many human tumours, and investigations from several laboratories show that such alterations, taken together, are the most frequent changes detected in cancer cells. The present paper describes mutational analysis by polymerase chain reaction-single-strand conformation polymorphism (PCR/SSCP) and nucleotide sequence analysis of the genes coding for the p15, p53 and N-ras proteins in 26 metastases from 25 melanoma patients. The registered mutation frequencies add together with previously registered mutations in p16 in the same patient samples to a substantial total frequency of 44% of patients with mutation in at least one of the investigated genes. These results show the occurrence of heterogeneous defects among components of the cell cycle controlling machinery in a human melanoma tumour sample collection and demonstrate that the total frequency of detected alterations increases with the number of cell cycle controlling genes included in the screening panel.

Full text

PDF
936

Images in this article

937Figure 1
on p.937

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albino A. P., Nanus D. M., Mentle I. R., Cordon-Cardo C., McNutt N. S., Bressler J., Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989 Nov;4(11):1363–1374. [PubMed] [Google Scholar]
  2. Ball N. J., Yohn J. J., Morelli J. G., Norris D. A., Golitz L. E., Hoeffler J. P. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994 Mar;102(3):285–290. doi: 10.1111/1523-1747.ep12371783. [DOI] [PubMed] [Google Scholar]
  3. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779–827. doi: 10.1146/annurev.bi.56.070187.004023. [DOI] [PubMed] [Google Scholar]
  4. Bos J. L. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689. [PubMed] [Google Scholar]
  5. Buchman V. L., Chumakov P. M., Ninkina N. N., Samarina O. P., Georgiev G. P. A variation in the structure of the protein-coding region of the human p53 gene. Gene. 1988 Oct 30;70(2):245–252. doi: 10.1016/0378-1119(88)90196-5. [DOI] [PubMed] [Google Scholar]
  6. Caldas C., Hahn S. A., da Costa L. T., Redston M. S., Schutte M., Seymour A. B., Weinstein C. L., Hruban R. H., Yeo C. J., Kern S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994 Sep;8(1):27–32. doi: 10.1038/ng0994-27. [DOI] [PubMed] [Google Scholar]
  7. Cannon-Albright L. A., Goldgar D. E., Meyer L. J., Lewis C. M., Anderson D. E., Fountain J. W., Hegi M. E., Wiseman R. W., Petty E. M., Bale A. E. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992 Nov 13;258(5085):1148–1152. doi: 10.1126/science.1439824. [DOI] [PubMed] [Google Scholar]
  8. Castresana J. S., Rubio M. P., Vázquez J. J., Idoate M., Sober A. J., Seizinger B. R., Barnhill R. L. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer. 1993 Oct 21;55(4):562–565. doi: 10.1002/ijc.2910550407. [DOI] [PubMed] [Google Scholar]
  9. Clurman B. E., Roberts J. M. Cell cycle and cancer. J Natl Cancer Inst. 1995 Oct 18;87(20):1499–1501. doi: 10.1093/jnci/87.20.1499. [DOI] [PubMed] [Google Scholar]
  10. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995 Sep;147(3):545–560. [PMC free article] [PubMed] [Google Scholar]
  11. Filmus J., Robles A. I., Shi W., Wong M. J., Colombo L. L., Conti C. J. Induction of cyclin D1 overexpression by activated ras. Oncogene. 1994 Dec;9(12):3627–3633. [PubMed] [Google Scholar]
  12. Flørenes V. A., Oyjord T., Holm R., Skrede M., Børresen A. L., Nesland J. M., Fodstad O. TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer. 1994 Feb;69(2):253–259. doi: 10.1038/bjc.1994.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldstein A. M., Dracopoli N. C., Engelstein M., Fraser M. C., Clark W. H., Jr, Tucker M. A. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet. 1994 Mar;54(3):489–496. [PMC free article] [PubMed] [Google Scholar]
  14. Graña X., Reddy E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995 Jul 20;11(2):211–219. [PubMed] [Google Scholar]
  15. Gruis N. A., Weaver-Feldhaus J., Liu Q., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol. 1995 May;146(5):1199–1206. [PMC free article] [PubMed] [Google Scholar]
  16. Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994 Sep 15;371(6494):257–261. doi: 10.1038/371257a0. [DOI] [PubMed] [Google Scholar]
  17. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821–1828. doi: 10.1126/science.7997877. [DOI] [PubMed] [Google Scholar]
  18. Hedrum A., Pontén F., Ren Z., Lundeberg J., Pontén J., Uhlén M. Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. Biotechniques. 1994 Jul;17(1):118-9, 122-4, 126-9. [PubMed] [Google Scholar]
  19. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  20. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  21. Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A., Ally D. S., Sheahan M. D., Clark W. H., Jr, Tucker M. A., Dracopoli N. C. Germline p16 mutations in familial melanoma. Nat Genet. 1994 Sep;8(1):15–21. doi: 10.1038/ng0994-15. [DOI] [PubMed] [Google Scholar]
  22. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  23. Kishimoto Y., Murakami Y., Shiraishi M., Hayashi K., Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 1992 Sep 1;52(17):4799–4804. [PubMed] [Google Scholar]
  24. Lagerkvist A., Stewart J., Lagerström-Fermér M., Landegren U. Manifold sequencing: efficient processing of large sets of sequencing reactions. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2245–2249. doi: 10.1073/pnas.91.6.2245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  26. Mori T., Miura K., Aoki T., Nishihira T., Mori S., Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 1994 Jul 1;54(13):3396–3397. [PubMed] [Google Scholar]
  27. Naito M., Satake M., Sakai E., Hirano Y., Tsuchida N., Kanzaki H., Ito Y., Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res. 1992 Oct;83(10):1030–1036. doi: 10.1111/j.1349-7006.1992.tb02717.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  29. Ohta M., Nagai H., Shimizu M., Rasio D., Berd D., Mastrangelo M., Singh A. D., Shields J. A., Shields C. L., Croce C. M. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 1994 Oct 15;54(20):5269–5272. [PubMed] [Google Scholar]
  30. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045–11049. doi: 10.1073/pnas.91.23.11045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Otsuki T., Clark H. M., Wellmann A., Jaffe E. S., Raffeld M. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 1995 Apr 1;55(7):1436–1440. [PubMed] [Google Scholar]
  32. Platz A., Ringborg U., Brahme E. M., Lagerlöf B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res. 1994 Jun;4(3):169–177. doi: 10.1097/00008390-199406000-00005. [DOI] [PubMed] [Google Scholar]
  33. Platz A., Ringborg U., Grafström E., Hög A., Lagerlöf B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res. 1995 Apr;5(2):101–106. doi: 10.1097/00008390-199504000-00005. [DOI] [PubMed] [Google Scholar]
  34. Platz A., Ringborg U., Lagerlöf B., Lundqvist E., Sevigny P., Inganäs M. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer. 1996 Feb;73(3):344–348. doi: 10.1038/bjc.1996.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  36. Volkenandt M., Schlegel U., Nanus D. M., Albino A. P. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res. 1991 Feb;4(1):35–40. doi: 10.1111/j.1600-0749.1991.tb00311.x. [DOI] [PubMed] [Google Scholar]
  37. Zhou X., Tarmin L., Yin J., Jiang H. Y., Suzuki H., Rhyu M. G., Abraham J. M., Meltzer S. J. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene. 1994 Dec;9(12):3737–3741. [PubMed] [Google Scholar]
  38. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]
  39. van 't Veer L. J., Burgering B. M., Versteeg R., Boot A. J., Ruiter D. J., Osanto S., Schrier P. I., Bos J. L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol. 1989 Jul;9(7):3114–3116. doi: 10.1128/mcb.9.7.3114. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES